Boardroom Alpha
Boardroom Alpha
QTTB · Additional Proxy Materials (DEFA14A) · Filed April 30, 2026

Q32 Bio Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 30, 2026
Ticker
QTTB
Accession
0001193125-26-193953
Boardroom Alpha · Filing insights

Q32 Bio Inc. presents a board-backed slate and routine governance items; board urges vote For all proposals.

About Q32 Bio Inc
Market cap
$214M
1Y TSR
+317.4%
3Y TSR
−26.5%
Board grade
C
Sector
Healthcare
CEO
Jodie Pope Morrison
Last annual meeting: Jun 12, 2026 · View full Q32 Bio Inc profile →
DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

 

Preliminary Proxy Statement

 

 

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

 

 

Definitive Proxy Statement

 

 

 

 

Definitive Additional Materials

 

 

 

 

Soliciting Material Pursuant to §240.14a-12

 

 

Q32 Bio Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

 

No fee required

 

 

 

 

Fee paid previously with preliminary materials

 

 

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 


 

img34142232_0.jpg

Your Vote Counts! Q32 BIO INC 2026 Annual Meeting Vote by June 11, 2026 11:59 PM ET Q32 BIO INC. 830 WINTER STREET WALTHAM, MA 02451 V92532-P42416 You invested in Q32 BIO INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2026 8:30 AM Eastern Time Virtually at: www.virtualshareholdermeeting.com/QTTB2026*Please check the meeting materials for any special requirements for meeting attendance.


img34142232_1.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review the proxy materials before voting. Voting Items Board Recommends 1. To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal; Nominees: 1a. Kathleen LaPorte 1b. Jodie Morrison 1c. Arthur Tzianabos, Ph.D. 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; 3. To approve, on a non-binding, advisory basis, the compensation of our named executive officers; and 4. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V92533-P42416


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Q32 Bio Inc (QTTB)

Reference

Frequently asked questions

When did Q32 Bio Inc file this DEFA14A?
Q32 Bio Inc (QTTB) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. The accession number assigned by EDGAR is 0001193125-26-193953.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Q32 Bio Inc. presents a board-backed slate and routine governance items; board urges vote For all proposals. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Q32 Bio Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Q32 Bio Inc has filed under CIK 1661998, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer